Welcome to the 10th CAR-TCR Summit!
The cell therapy field has seen a lot of positive momentum recently. With Leucid Bio announcing the treatment of first patient in the AERIAL trial, CARsgen announcing preliminary clinical data for their allogeneic CAR-T, Sail Biomedicine presenting preclinical in vivo data for their autoimmune CAR-T, and Cabaletta announcing plans for an anticipated 2027 BLA submission, there is so much to be excited about! Don’t sit back and watch. Join the 10th Anniversary of the CAR-TCR Summit to reflect on a decade of progress whilst engaging in solutions-driven discussions that will empower you to tackle cell therapy development challenges to help shape the future of the field.
Built in collaboration with industry veterans including AstraZeneca, Cabaletta Bio, Arsenal Bio, Bristol Myers Squibb, Kyverna Therapeutics, T-knife Therapeutics, and Umoja Biopharma, this meeting will equip you to overcome challenges across the entire development landscape - spanning durability, manufacturing timelines, potency assay matrix, solid tumor targeting, biomarker data, high cost of goods, scale up and scale out, and more, to make rapid advancements in the clinic and beyond.
Whether your focus is on Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, or Analytical Development you can expect to gain in-depth insights across the entire cell therapy value chain.
Just Registered:
Your Complete Guide to the CAR-TCR Summit is Here:
Key Highlights of the 10th CAR-TCR Summit:
Holistic Coverage of Multiple Cell Types
51% CAR-Ts, 20% TCRs, 18% NK, Gamma Delta, Macrophages, TILs and Tregs, and 11% multiple cell types to give full visibility of advancements in cell therapy
Comprehensive Coverage of Indications
Spanning haem, and solid tumors, to autoimmune indications - understand the challenges when targeting different indications from cell engineering to patient recruitment nuances
Brand New Biotech & Pharma Partnering Day
Join some of the key players involved in recent mergers and acquisitions, including AstraZeneca, Johnson & Johnson, and Merck, to gain insider insights into the decision-making processes
New Clinical Data
from Capstan Therapeutics on in vivo CAR-T, Legend Biotech on solid tumors targeting, and MiNK Therapeutics on the success of cell therapy beyond oncology
Full Cell Therapy Landscape Coverage
Gain competitive insight across multiple scopes of indications from oncology to autoimmune to cover the growing trial expansion and ensure you stay ahead of the curve
Attending Companies:
Expert Speakers Include:
Christopher Tan
Executive Director - Business Development, Infectious Diseases, Vaccines, Oncology & Licensing
Merck
Mark Cobbold
Senior Vice President & Head Of Oncology Discovery Cell Therapy, Oncology Research & Development
AstraZeneca
Network with Experts from the Entire Cell Therapy Ecosystem
“I’m excited to join this year’s summit to exchange bold ideas, share first-in-human data on iNKT cell therapy, and explore how we can expand the reach of cell therapy to patients suffering from autoimmune diseases. It’s a critical moment for collaboration and scientific innovation as we move beyond oncology.”
MiNK Therapeutics, 2025 Speaker
Lead Partner
Expertise Partners
